Latest Richter's transformation Stories
Doctors at Dartmouth-Hitchcock's Norris Cotton Cancer Center (NCCC) have found a combination of drugs to potentially treat chronic lymphocytic leukemia (CLL) more effectively. The research was published online on May 3, 2013, and it will appear as a letter in the journal Leukemia, a publication of the prestigious Nature Publishing Group. The study helps address a basic problem of treating CLL. CLL lives both in the blood in circulation, and in lymph nodes and bone marrow. The former is...
-Nine Ibrutinib Presentations at the American Association of Cancer Research - SUNNYVALE, Calif., April 8, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today announced results from a Phase II trial of the investigational oral agent ibrutinib which demonstrated rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of characteristics that predict poor outcomes to...
CHICAGO, June 4, 2012 /PRNewswire/ -- Pharmacyclics, Inc (Nasdaq: PCYC) announced today updated results from three trials of Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), for the treatment of patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). "This meeting at ASCO has been a continued affirmation of the promising activity and clinical benefit of ibrutinib in CLL. It will be exciting to move this toward definitive Phase III study...
PCI-32765 applies molecularly aimed attack to disease usually treated with chemotherapy combinations A new, targeted approach to treating chronic lymphocytic leukemia has produced durable remissions in a Phase I/II clinical trial for patients with relapsed or resistant disease, investigators report at the 53rd Annual Meeting of the American Society of Hematology. "PCI-32765, one of a new class of experimental drugs called B cell receptor inhibitors, has shown impressive potential in...
New drug, in early clinical testing, offers some cluesWhile testing a new drug designed to treat chronic leukemia, researchers at Cleveland Clinic discovered new markers that could identify which patients would receive maximum benefit from the treatment.This information was released in the online edition of Blood, a weekly medical journal published by the American Society of Hematology.Chronic lymphocytic leukemia (CLL), a cancer of the white blood cells that is incurable with standard...
WHITE PLAINS, NY, June 16, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society is committed to bringing the most current information about blood cancers to all patients and is pleased to announce a unique educational opportunity for Spanish- and Portuguese-speaking patients with chronic lymphocytic leukemia (CLL) and their families. On Tuesday, June 21 from 12:00 to 1:00 PM Eastern Time, Dr. Susan O'Brien, an international leukemia expert from The University of Texas MD Anderson Cancer...
A paper published online on June 13 in the Journal of Experimental Medicine (www.jem.org) identifies new gene mutations in patients with chronic lymphocytic leukemia (CLL)"”a disease often associated with lack of response to chemotherapy and poor overall survival.CLL is the most common leukemia in the Western world, but the disease varies greatly from patient to patient with regard to prognosis, survival, and disease course. In attempt to understand the genetic basis for this heterogeneity,...
WHITE PLAINS, N.Y., May 26, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society is committed to bringing the most current information about blood cancers to all patients and is pleased to announce a unique educational opportunity for Spanish- and Portuguese-speaking patients with chronic lymphocytic leukemia (CLL) and their families. On Tuesday, June 21 from 12:00 to 1:00 PM Eastern Time, Dr. Susan O'Brien, an international leukemia expert from The University of Texas MD Anderson...
Potential mechanism identifiedIn research to be presented at the American Society of Hematology (ASH) annual meeting, investigators at Dana-Farber Cancer Institute in Boston offer a new explanation of why chronic lymphocytic leukemia (CLL) tends to recur in the lymph nodes and bone marrow after being cleared from the bloodstream by chemotherapy. Their findings will be reported during in an oral session on Monday, Dec. 6, at 4:45 p.m. in room 315 of the Orange County Convention Center.To...
WASHINGTON, July 1 /PRNewswire-USNewswire/ -- Allogeneic (donor-derived) stem cell transplant (alloSCT) may be a promising option for patients with treatment-resistant chronic lymphocytic leukemia (CLL), regardless of the patient's underlying genetic abnormalities, according to the results of a study published online today in Blood, the journal of the American Society of Hematology. About 15,000 new CLL cases were diagnosed in the United States in 2009 and about 4,000 deaths were...
